Promising Outlook for Axsome Therapeutics Driven by Auvelity’s Strong Market Performance and Growth Prospects
Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...
Zacks.com on MSN5d
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...
TD Cowen lifts Axsome stock target to $155, maintains Buy rating
TD Cowen, a well-established research firm, increased its price target on Axsome Therapeutics (NASDAQ:AXSM) shares, raising the figure to $155 from the previous target of $125. The firm reaffirmed its ...
pharmaphorum5d
Axsome bounces back as FDA clears depression drug
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...
William Blair Reiterates “Outperform” Rating for Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at ...
What is HC Wainwright’s Estimate for AXSM FY2024 Earnings?
HC Wainwright upped their FY2024 earnings estimates for Axsome Therapeutics in a research note issued to investors on Tuesday ...
Seeking Alpha2d
AXSM Axsome Therapeutics, Inc.
The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of ...